Erin Hofstatter MD ABRCC-2

    Clinical Researchers Showcase Series - March 2019

    Translational Medicine Research:

 View from the Trenches Newsletter

box_top.gif

Brought to you by:

Criterium Logo Alt Tag Line w Globe Banner 2

Translational science is motivated by the need to provide effective treatments to the right patients at the right doses for a specific disease indication). The term is used mostly in the health sciences and refers to real-time translation of bench science, conducted only
in a lab, to bedside clinical practice or dissemination to population-based community interventions. (Source: NIH)


from the
Academic Breast Cancer Consortium

ABRCC Researcher Spotlight:

MEET Erin Wysong Hofstatter, MD

Yale University Cancer Center, New Haven, CT

ABRCC Investigator


Dr. Erin Hofstatter, Associate Professor of Medicine (Medical Oncology) and Co-Director of the Cancer Genetics and Prevention Program at Smilow Cancer Hospital.

 

Dr. Hofstatter is a medical oncologist with clinical and research expertise in breast cancer and clinical breast cancer genetics. She serves as a breast medical oncologist at the Breast Center at Smilow Cancer Hospital, where she sees and treats patients with breast cancer.  Dr. Hofstatter also serves as the Co-Director of the Smilow Cancer Genetics and Prevention Program/Director of the Breast Cancer Prevention Clinic, where she sees those patients who may be at increased risk of breast cancer due to a hereditary/genetic predisposition, a strong family history, or breast atypia. Her education and training include:  Resident at Mount Auburn Hospital; Fellow at Beth Israel Deaconess Medical Center and she received her MD from University of Connecticut School of Medicine (2003).

 

See Dr Hofstatter on YouTube

 

Dr. Hofstatter is one of 13 recipients of the 2016 National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award (CCITLA).   The award recognizes and supports outstanding mid-career clinical investigators at NCI-designated Cancer Centers who are working to improve the lives of people with cancer through extensive involvement in NCI-funded collaborative clinical trials and whose leadership, participation and activities promote clinical trials and research.

 

About Yale Cancer Center
In the history of cancer treatment, Yale is perhaps best known as the institution where cancer chemotherapy and the entire field of cancer drug development was discovered and the very first cancer drug was administered in 1942. In 1953 Yale created the first department of pharmacology, the precursor to the section of medical oncology, to focus on cancer drug development and treatment. Yale Cancer Center became an inaugural National Cancer Institute Comprehensive Cancer Center in 1974 under the National Cancer Act. It is one of only 49 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in southern New England. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment. Learn more at: https://www.yalecancercenter.org/

box_bottom.gif

About the CONSORTIA MODEL 
for Translational Research

The important conceptual difference between the two predominant research group approaches used today (a Clinical Trials Group vs. Consortia) is seen in this consortia model.  With its highly experienced clinical scientists, ABRCC becomes involved on an intellectual advisory level with every step of clinical investigation in a breast cancer study. Classical clinical trials groups "just run the study" with the main substantive role being patient accrual.

 

To read more on ABRCC and the details of why the consortia model creates fast results, please visit our website.


The Oncology Consortia of Criterium

The Oncology Consortia of Criterium Global CRO are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise:

  • AGICC:  Academic GI Cancer Consortium
  • AMyC:  Academic Myeloma Consortium
  • ATOMIC:  Academic Thoracic Oncology Medical Investigators Consortium
  • ABRCC:  Academic Breast Cancer Consortium

ABRCC Cube FULL Logo 2

Read more about Criterium Inc Global CRO

and The Oncology Consortia of Criterium on our website